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Introduction
Chromosome segregation is controlled by the mitotic spindle, 
which attaches sister chromatids via kinetochores, which are 
multiprotein complexes located on centromeric DNA (Musacchio 
and Salmon, 2007; Cheeseman and Desai, 2008). Correct chromo­
some  segregation  requires  that  kinetochore  pairs  bind  to   
microtubules (MTs) emanating from opposite spindle poles in 
a bipolar manner and that they control the forces that align the 
chromosomes on a metaphase plate. Kinetochores also monitor 
bipolar MT attachment and control mitotic progression through 
the spindle checkpoint, which arrests cells before anaphase by 
inhibiting the anaphase­promoting complex in the presence of in­
correctly attached chromosomes (Musacchio and Salmon, 2007).
The spindle checkpoint requires the conserved proteins 
Mad1, Mad2, Bub1, Bub3, Mad3/BubR1, and Mps1, which ac­
cumulate on unattached kinetochores during mitosis (Musacchio 
and Salmon, 2007). The protein kinase Bub1 is not only essen­
tial for the spindle checkpoint, it is also required for correct   
kinetochore–MT attachments (Williams et al., 2007). Bub1 loss 
delays the formation of stable end­on attachments, causing an 
accumulation of lateral kinetochore–MT attachments (Gillett   
et al., 2004; Meraldi and Sorger, 2005). The two functions of 
Bub1 are conserved, as its inactivation causes loss of spindle 
checkpoint and severe chromosome segregation defects in all 
tested eukaryotes (Bernard et al., 1998; Warren et al., 2002; 
Meraldi and Sorger, 2005; Perera et al., 2007). Studies in yeast 
and vertebrates have identified several downstream targets that 
require Bub1 for kinetochore binding, including Mad1, Mad2, 
and BubR1, the MT–depolymerase mitotic centromere­associated 
kinesin (MCAK), and the outer kinetochore protein, centro­
mere  protein  F  (CENP­F;  Sharp­Baker  and  Chen,  2001; 
Warren et al., 2002; Johnson et al., 2004; Meraldi et al., 2004; 
Boyarchuk et al., 2007; Huang et al., 2007; Kiyomitsu et al., 
2007). Moreover, Bub1 regulates the targeting of cohesion pro­
tein Sgo1 (shugoshin) to the centromere through PP2A (Tang   
et al., 2004b, 2006; Kitajima et al., 2005).
Bub1 deregulation is also linked to apoptosis and tumori­
genesis. Reduction of Bub1 levels can lead to tumorigenesis,   
senescence, and p53­dependent and ­independent apoptosis 
(Gjoerup et al., 2007; Jeganathan et al., 2007; Niikura et al., 2007), 
whereas a Bub1 knockout causes early embryonic lethality (Perera 
et al., 2007). Primary Bub1
/ mouse embryo fibroblasts lack a 
T
he kinetochore-bound protein kinase Bub1 performs 
two crucial functions during mitosis: it is essential   
for  spindle  checkpoint  signaling  and  for  correct   
chromosome alignment. Interestingly, Bub1 mutations 
are found in cancer tissues and cancer cell lines. Using 
an isogenic RNA interference complementation system 
in transformed HeLa cells and untransformed RPE1 cells, 
we investigate the effect of structural Bub1 mutants on 
chromosome segregation. We demonstrate that Bub1 
regulates mitosis through the same mechanisms in both 
cell  lines,  suggesting  a  common  regulatory  network.   
Surprisingly, Bub1 can regulate chromosome segrega-
tion in a kinetochore-independent manner, albeit at lower 
efficiency.  Its  kinase  activity  is  crucial  for  chromosome 
alignment but plays only a minor role in spindle check-
point  signaling.  We  also  identify  a  novel  conserved 
motif within Bub1 (amino acids 458–476) that is essen-
tial for spindle checkpoint signaling but does not regulate 
chromosome alignment, and we show that several cancer-
related Bub1 mutants impair chromosome segregation, 
suggesting a possible link to tumorigenesis.
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different Bub1 mutants. This system is built on the integration 
of a single Flp recombination target (FRT) site into the genome 
and the subsequent integration of Bub1 expression constructs 
via Flp­mediated intermolecular DNA recombination. This guar­
antees that phenotypical differences observed in different Bub1 
mutant cell lines are not a result of the varying genetic back­
ground of the integration site. Moreover, all stable cell lines ex­
press RNAi­resistant Bub1 mutants, allowing the exclusive 
depletion of endogenous Bub1 (Fig. 1 A).
The Flp­In system was integrated into a HeLa cell line ex­
pressing histone H2B–monomeric RED protein (mRED) in 50% 
of the cells to allow both immunofluorescence measurements 
and the monitoring of chromosome segregation by time­lapse 
imaging. Southern blot analysis with a probe directed against the 
lacZ gene localized on the pFRT/lacZeo vector identified one 
HeLa Flp­In clone with a single FRT integration site, and FISH 
analysis with a hybridization sample directed against lacZ con­
firmed the uniqueness of the integration site (Fig. 1, B and C).
Depletion of Bub1 by RNAi abrogates the spindle check­
point and impairs chromosome congression (Meraldi and Sorger, 
2005). We tested the efficiency of Bub1 RNAi in HeLa Flp­In cells 
to confirm that FRT integration did not affect the Bub1 RNAi pheno­
type. Immunoblotting with Bub1 antibodies showed that Bub1 
RNAi depleted Bub1, and quantification by immunofluorescence 
indicated that Bub1 protein levels at kinetochores were reduced to 
3% when compared with control­treated cells (Fig. 1, D–F). To 
test for spindle checkpoint abrogation, cells were treated for 16 h 
with the MT­depolymerizing drug nocodazole, which abrogates 
kinetochoreMT attachment, resulting in spindle checkpoint–
dependent mitotic arrest and a strong enrichment of Mad1, Mad2, 
and BubR1 at kinetochores (Hoffman et al., 2001). Depletion of 
Bub1 in HeLa Flp­In cells abrogated both the mitotic arrest, as   
visualized by phase­contrast microscopy, and the recruitment of 
Mad1, Mad2, and BubR1 to kinetochores, as quantified by immuno­
fluorescence (Fig. 1, G and H). We next measured whether Bub1 
depletion also impaired chromosome congression. We treated our 
cells for 1 h with the proteasome inhibitor MG132, which arrests 
cells in metaphase in a spindle checkpoint–independent manner 
(Rock et al., 1994), fixed, and stained them for DNA, kinetochores, 
and the mitotic spindle. We identified cells with a metaphase plate, 
indicative of a metaphase arrest, and quantified the percentage of 
cells with unaligned chromosomes (chromosomes were counted   
as unaligned when located outside of the central 30% of the 
mitotic spindle). Consistent with previous studies, Bub1 depletion 
strongly increased the percentage of HeLa Flp­In cells with un­
congressed chromosomes when compared with control depletion 
(55 vs. 16%; Fig. 1 I; Johnson et al., 2004; Meraldi and Sorger, 
2005) but did not affect chromosome cohesion (not depicted;   
Perera et al., 2007). We conclude that FRT integration did not af­
fect the Bub1 RNAi phenotype.
Expression of Bub1–wild type (wt) 
complements Bub1 RNAi
We next tested the ability of exogenous Bub1­wt to comple­
ment Bub1 RNAi when stably expressed in HeLa Flp­In cells. 
Bub1­wt encodes for wt Bub1 protein fused at its C terminus 
with a Flag­EGFP tag and carries four silent mutations in the 
functional spindle checkpoint, show aberrant chromosome segre­
gation, and fail to proliferate (Perera et al., 2007). In humans, ab­
errant Bub1 gene expression is detected in esophageal, gastric, and 
colon tumors, melanoma, and breast cancer cell lines (Shigeishi   
et al., 2001; Shichiri et al., 2002; Doak et al., 2004). Moreover, 
point mutations and deletions were found in leukemia, lymphoma, 
and thyroid cancer as well as colon and lung cancer cell lines   
(Cahill et al., 1998; Ohshima et al., 2000; Ru et al., 2002; Shichiri 
et al., 2002). However, the functional consequence of these muta­
tions is unknown.
Bub1 contains several domains, including an N­terminal 
domain, which binds to the kinetochore protein KNL1/Blinkin 
(Kiyomitsu et al., 2007), a Bub3­binding domain (Taylor et al., 
1998), and a C­terminal kinase domain. The role of these do­
mains and interactions has been studied in Saccharomyces cere-
visiae and Schizosaccharomyces pombe, revealing conserved 
features of ScBub1 and SpBub1 but also species­dependent dif­
ferences: Bub3 is essential for Bub1 function in S. cerevisiae 
but dispensable for checkpoint control in S. pombe, implying 
that SpBub1 regulates the spindle checkpoint without SpBub3 
(Roberts et al., 1994; Warren et al., 2002; Tange and Niwa, 
2008). The role of the kinase domain is also different; in both 
yeasts, it regulates kinetochore–MT attachment, but inacti­
vation of the kinase does not perturb the checkpoint in S. cere-
visiae, although partially compromising the checkpoint in   
S. pombe (Warren et al., 2002; Yamaguchi et al., 2003; Fernius 
and Hardwick, 2007).
Given these phenotypical variations in fungal systems, the 
role of the Bub1 domains and of its interaction partners remains 
unclear or has been studied only in a punctual manner in human 
cells. It has been reported that, in contrast to yeast, the kinase do­
main is required for the spindle checkpoint (Kang et al., 2008) 
and that the KNL1­binding domain is important for chromosome 
congression, raising the question as to which extent the functions 
are conserved (Warren et al., 2002; Vanoosthuyse et al., 2004; 
Kiyomitsu et al., 2007). An equally important question, which 
could not be studied in yeast, is whether cancer­related Bub1 mu­
tations impair chromosome segregation. Until now, the lack of   
robust genetic tools prevented the analysis of multiple human 
Bub1 mutants. We therefore established a genetic system in human 
cells, i.e., expressing stable Bub1 mutants in an isogenic RNAi 
complementation system, and combined it with a cell biological 
analysis. Our results indicate that Bub1 can regulate chromo­
some segregation in a kinetochore­independent manner; we iden­
tify a novel conserved motif, which is essential for spindle 
checkpoint signaling, and we demonstrate that the kinase activity 
is essential for chromosome alignment but not for the spindle 
checkpoint. Finally, we find that cancer­related Bub1 mutations 
deregulate chromosome segregation, suggesting a functional link 
to tumorigenesis.
Results
Construction of HeLa Flp-In cell lines
To investigate how human Bub1 regulates chromosome segre­
gation at the molecular level, we generated a Bub1 RNAi 
complementation system based on stable cell lines expressing 843 ANALYZING BUB1 FUNCTION AT THE MOLECULAR LEVEL • Klebig et al.
Figure 1.  Integration of the FRT site into the genome of HeLa cells does not affect the Bub1 RNAi phenotype. (A) Schematic diagram illustrating the genera-
tion of stable Flp-In and Bub1 mutant cell lines. (B) Southern blot against the DNA of two HeLa Flp-In clones probed for lacZ. The clone in the right lane 
was selected. The transfected vector pFRT/lacZeo was used as a positive control, and DNA from untransfected HeLa Kyoto H2B-mRED cells were used 
as negative control. (C) FISH analysis of selected HeLa Flp-In cells with a probe against lacZ. The arrow indicates positive FISH signal. Bar, 5 µm. (D–I) 
Characterization of HeLa Flp-In cells treated with control or Bub1 RNAi. (D) Immunoblot of whole cell lysates probed with Bub1 and -tubulin antibodies. 
Black line indicates that intervening lanes have been spliced out. (E) Immunofluorescence images of mitotic cells stained with DAPI (DNA), Bub1 antisera 
(green), and CREST antisera (red, kinetochores). Bar,10 µm. (F) Quantification by immunofluorescence of Bub1 levels at kinetochores. (G) Mitotic index of 
HeLa Flp-In cells treated for 16 h with or without nocodazole. (H) Quantification by immunofluorescence of Mad1 (blue), Mad2 (red), and BubR1 (yellow) 
levels at kinetochores. (I) Cumulative plot of the percentage of metaphase cells with unaligned chromosomes after a 1-h MG132 treatment. Insets show a 
higher magnification view of a single kinetochore. Error bars represent standard deviation.JCB • VOLUME 185 • NUMBER 5 • 2009   844
Figure 2.  Bub1-Flag-EGFP wt complements Bub1 RNAi. (A) RT-PCR of a region within the 3 UTR of Bub1, a region within the ORF of Bub1, and   
the housekeeping gene RPS9. (B) Immunoblot of lysates of Bub1-wt cells treated with RNAi as indicated and probed with Bub1 and -tubulin antibodies. 
(C) Immunofluorescence images of mitotic cells stained with DAPI (DNA), GFP, or Bub1 antisera (green) and CREST antisera (red, kinetochores). Bar,   
10 µm. (D) Quantification by immunofluorescence of Bub1 levels in total cells. (E) Mitotic index of the indicated cells treated with or without nocodazole for 
16 h. (F) Quantification of TUNEL-positive cells after nocodazole and Bub1 RNAi. (G) Quantification by immunofluorescence of Mad1, Mad2, and BubR1 
levels on kinetochores. (H) Cumulative plot of percentage of metaphase cells with unaligned chromosomes after a 1-h MG132 treatment. (I) Cumulative 
frequency plots of chromosome alignment time using nuclear breakdown (NBD) as t = 0. Insets show a higher magnification view of a single kinetochore. 
Error bars represent standard deviation.845 ANALYZING BUB1 FUNCTION AT THE MOLECULAR LEVEL • Klebig et al.
congression in Bub1­wt cells compared with control RNAi–
treated cells, as 50% of the cells aligned all their chromosomes 
after 17 min in both depletions (Fig. 2 I). In contrast, in Flp­In 
HeLa cells, Bub1 depletion caused a severe delay of congres­
sion (after 8 h, only 36% of the cells had aligned all their chromo­
somes; Fig. 2 I). This indicated that Bub1­wt also complemented 
Bub1 RNAi in terms of chromosome congression. Overall, we 
conclude that we have established a system that allows the func­
tional comparison of Bub1 mutants. We further note that exoge­
nous Bub1 is expressed at roughly 70% of endogenous Bub1 
and that it complements the spindle checkpoint only to 80%, 
suggesting that we are working with a sensitized system.
Differential effects of Bub1  
mutants on spindle checkpoint and 
chromosome congression
Alignments  of  fungal  and  vertebrate  Bub1  sequences  reveal 
several conserved domains, including two previously uncharac­
terized, conserved motifs. To investigate the different roles of 
Bub1, we generated mutants lacking one of the following do­
mains: (a) the KNL1­binding domain, which is required for   
kinetochore localization, (b) the Bub3­binding domain, (c) the 
conserved motif I (aa 458–476), (d) the conserved motif II   
(aa 740–766), (e and f) two different catalytically inactive mutants 
(one lacking the whole kinase domain and the other harboring a 
lysine to arginine mutation in the catalytic motif and an aspar­
tate to asparagine mutation in the DFG motif, which both abol­
ish kinase activity; van den Heuvel and Harlow, 1993), and 
(g) a truncated Bub1 fragment (dominant negative [DN]; aa 1–332), 
which acts in a DN manner when overexpressed (Fig. 3, A–D; 
Taylor and McKeon, 1997).
All of these mutants were expressed in stable HeLa Flp­In 
cells as Flag­EGFP fusion proteins. We quantified by immuno­
fluorescence their total cellular levels (Fig. 3 E) and their spe­
cific abundance on unattached kinetochores (Fig. 3, F and J) in 
Bub1 RNAi–treated cells using GFP and Bub1 antibodies. All 
mutants were expressed at equal levels but showed distinct abil­
ities to bind unattached kinetochores; Bub1–∆kinase domain, 
Bub1–kinase dead, and Bub1­DN levels on kinetochores were 
similar to Bub1­wt (75–120% of Bub1­wt), whereas Bub1–
∆conserved motif I and II had a decreased ability to bind to   
kinetochores (40–60%). Finally, Bub1­∆KNL1–binding domain 
and  Bub1­∆Bub3–binding  domain  did  not  localize  to  un­
attached kinetochores.
Using the nocodazole and the MG132­based congression 
assays, we found that none of the tested mutants affected the 
spindle checkpoint or chromosome alignment, indicating that 
they did not act in a DN manner (Fig. 3, H and I). Interestingly, 
in the presence of endogenous Bub1, most of the mutants did not 
localize to kinetochores, suggesting, as previously reported, a low 
exchange rate of endogenous Bub1 at kinetochores (Fig. S1 E 
and not depicted; Shah et al., 2004).
We next evaluated the importance of the Bub1 domains 
with regard to apoptosis, spindle checkpoint, and chromosome 
congression in cells lacking endogenous Bub1. All Bub1 mu­
tants with the exception of the short Bub1­DN fully rescued the 
apoptotic response associated with Bub1 RNAi, suggesting that 
target RNAi site to guarantee Bub1-wt expression in a Bub1 
RNAi background.
We quantified the Bub1 mRNA levels in HeLa Flp­In and 
stable Bub1­wt cells treated with Bub1 or control RNAi by   
RT­PCR to confirm that Bub1-wt is resistant to Bub1 RNAi. 
We amplified a fragment of the coding Bub1 mRNA to measure 
total Bub1 expression and a fragment of the Bub1 3 untranslated 
region (UTR) to measure expression of endogenous Bub1. Bub1 
RNAi abolished expression of the Bub1 3 UTR in both cell 
lines when compared with control RNAi–treated cells, confirm­
ing the degradation of endogenous Bub1 mRNA (Fig. 2 A). 
Bub1 RNAi also abolished expression of total Bub1 in Flp­In 
cells but only reduced total Bub1 mRNA levels in Bub1­wt 
cells, indicating the presence of an RNAi­resistant exogenous 
Bub1-wt mRNA (Fig. 2 A). These results were confirmed at the 
protein level, as anti­Bub1 immunoblotting indicated that the 
endogenous Bub1 protein band of 130 kD disappeared after 
Bub1 RNAi, whereas a 170­kD Bub1­Flag­EGFP protein band 
remained in Bub1­wt cells (Fig. 2 B). In contrast, treatment 
with an alternative Bub1 siRNA, which targets a different se­
quence within Bub1, depleted both endogenous and exogenous 
Bub1 (Fig. 2 B). Quantitative anti­Bub1 immunofluorescence 
indicated that after Bub1 RNAi, total Bub1­wt was expressed at 
roughly 70% of endogenous Bub1 and localized to kinetochores 
(Fig. 2, C and D). In contrast, stable cell lines having incorpo­
rated an empty vector contained only 1% of endogenous Bub1 
after Bub1 RNAi (Fig. 2, C and D).
We next analyzed the efficiency at which Bub1­wt res­
cued the Bub1 RNAi phenotype. HeLa Flp­In cells treated with 
Bub1 RNAi did not arrest in mitosis when treated with no­
codazole (mitotic index of 15%), whereas control­depleted cells 
had a high mitotic index (48%). In contrast, both control­ and 
Bub1­depleted  Bub1­wt  cells  arrested  in  mitosis  after  a  no­
codazole treatment (39 vs. 58%; Fig. 2 E). Identical results were 
obtained with an untagged Bub1­wt, indicating that the weaker 
spindle checkpoint response was not a consequence of the   
C­terminal Flag­EGFP tag (Fig. 2 E). As Bub1 depletion also 
induces mitotic cell death, we used a TUNEL assay to quantify 
the extent to which a nocodazole treatment induced apoptosis 
(Jeganathan et al., 2007; Niikura et al., 2007). Although Bub1 
siRNA treatment increased the number of TUNEL­positive Flp­In 
cells (9 vs. 2% in control­depleted cells), stable expression of 
Bub1­wt with or without tag suppressed apoptosis (Fig. 2 F and 
Fig. S1 A). Immunofluorescence showed that Bub1­wt expres­
sion also restored recruitment of Mad1, Mad2, and BubR1 to 
kinetochores (Fig. 2 G; and Fig. S1, B–D). This indicated that 
Bub1­wt complements Bub1 RNAi in terms of spindle check­
point and apoptosis.
To test whether Bub1­wt also rescued chromosome con­
gression, we first detected the amount of uncongressed chromo­
somes in the MG132 assay and found that Bub1 RNAi did 
not increase the proportion of cells with unaligned chromo­
somes in Bub1­wt cells (Fig. 2 H). Second, we monitored chromo­
some congression by live cell imaging using the H2B­mRED 
signal. The time point of nuclear breakdown was set at t = 0, 
and the time until all chromosomes congressed on a metaphase 
plate was recorded. Bub1 RNAi did not affect chromosome JCB • VOLUME 185 • NUMBER 5 • 2009   846
Figure 3.  Differential ability of Bub1 mutants to complement apoptosis, spindle checkpoint signaling, and chromosome congression. (A) Schematic 
structure of Bub1 protein indicating conserved domains and a set of constructed Bub1 mutants. (B–D) Multiple sequence alignment of the Bub3-binding 
domain (B), the conserved domain I (C), and the conserved domain II (D) in five fungi and five vertebrates. Identical residues are in a black, residues 
conserved in ≥80% of the species are in a dark green, and similar residues in ≥80% of the species are in a light green background. Sc, S. cerevisiae; ca, 
Candida albicans; an, Aspergillus nidulans; nc, Neurospora crassa; sp, S. pombe; dr, Danio rerio; gg, Gallus gallus; xl, X. laevis; mm, Mus musculus; 
hs, Homo sapiens. (E) Immunofluorescence quantification of relative total cellular Bub1 levels with Bub1 (blue) and GFP antisera (red). Note that Bub1 
antibodies do not recognize Bub1-DN. (F) Immunofluorescence quantification of relative Bub1 levels on kinetochores with GFP antisera. (G) Quantification   847 ANALYZING BUB1 FUNCTION AT THE MOLECULAR LEVEL • Klebig et al.
Bub1­kinase activity, indicating that both domains are dispens­
able for the loading of MCAK and CENP­F (Fig. 5, A–D).   
In contrast, loss of Bub1 kinase activity abrogated Sgo1 targeting 
to centromeres, whereas deletion of the conserved motif I did 
not impair the recruitment of Sgo1 (Fig. 5, E and F). We con­
clude that in contrast to CENP­F and MCAK, Sgo1 recruitment 
is a crucial target of human Bub1 kinase activity.
Bub1 can also function when not bound  
to kinetochores
In a third step, we investigated the importance of kinetochore 
binding for Bub1 function by analyzing cells expressing Bub1­
∆KNL1–binding domain, which does not bind to kinetochores 
(Fig. 3, F and J). Interestingly, Bub1­∆KNL1–binding domain 
partially rescued both the spindle checkpoint (42% of Bub1­wt 
activity)  and  chromosome  congression  (72%  of  Bub1­wt   
activity; Fig. 3, H and I; and Fig. 4 A). The Bub1­∆KNL1–
binding domain mutant also rescued the ability to recruit sub­
stantial amounts of Mad1, Mad2, and MCAK to unattached 
kinetochores (Fig. 4, C–E; and Fig. 5, C and D). In contrast, 
recruitment of CENP­F, Sgo1, and BubR1 was impaired, indi­
cating that the presence of Bub1 at kinetochores is essential 
for the binding of these proteins to kinetochores (Fig. 4, C and F; 
and Fig. 5, A, B, E, and F). We conclude that Bub1 can exert 
some of its function when not bound to kinetochores and that 
loss of kinetochore binding only affects a subset of down­
stream Bub1 targets.
Bub1 mutants harboring cancer mutations
Because Bub1 mutations have been implicated in carcinogenesis, 
we also investigated whether three Bub1 point mutants found   
in cancer cell lines affect chromosome segregation: A130S is a 
conserved aa located in the KNL1­binding domain, and Y259C 
and H265N are located close to the Bub3­binding domain   
(Shichiri et al., 2002; Hempen et al., 2003). Immunofluores­
cence quantification revealed that all three mutants were ex­
pressed at levels comparable to Bub1­wt (Fig. 6 A). Bub1­Y259C 
and Bub1­H265N localized to kinetochores, whereas Bub1­
A130S localization at kinetochores was impaired, suggesting 
a disruption of the KNL1­binding domain (22% of Bub1­wt 
levels; Fig. 6, B and C).
None of the point mutants acted in a DN manner (Fig. 6,   
D and E), and all three mutants rescued the cell death phenotype 
(Fig. 6 F). In the absence of endogenous Bub1, Bub1­H265N res­
cued the spindle checkpoint, chromosome alignment, and the 
loading of all tested downstream factors (Fig. 6, D, E, G–J; and 
Fig. 7). Similar to the loss of the KNL1­binding domain, the 
Bub1­A130S mutation weakened the checkpoint, increased the 
rate of congression errors, and caused the loss of kinetochore 
binding of CENP­F, Sgo1, and BubR1 but not of MCAK, Mad1, 
or Mad2 (Fig. 6, D, E, G–J; and Fig. 7).
cell death associated with Bub1 loss is not associated with a 
particular domain (Fig. 3 G). This also indicated that all of our 
mutants are biologically active, excluding misfolding artifacts. 
We  also  found  that  both  Bub1­∆Bub3–binding  domain  and 
Bub1­DN cells could not activate the spindle checkpoint or 
align chromosomes after Bub1 RNAi (Fig. 3, H and I). Neither 
of these two mutants rescued kinetochore binding of Mad1, 
Mad2, BubR1, MCAK, Sgo1, or CENP­F, indicating that Bub3 
binding is essential for Bub1 chromosome segregation func­
tions in human cells and that expression of the DN domain does 
not rescue any Bub1 function (Fig. S2, A and B). Expression of 
Bub1–∆conserved motif II only weakly complemented the 
spindle checkpoint (42%) and chromosome congression (42%), 
suggesting that it plays an important role for Bub1 function 
(Fig. 3, H and I). This was also reflected at the level of the Bub1 
downstream targets, as loss of the conserved domain II resulted 
in  a  reduced  kinetochore  binding  of  Mad1,  Mad2,  BubR1, 
MCAK, CENP­F, and Sgo1 (Fig. S2, A and B).
Complementing roles of Bub1–conserved 
domain I and kinase domain
We next focused on the domains that were specifically required 
for one function of Bub1: the two catalytically inactive mutants, 
Bub1–∆kinase domain and Bub1–kinase dead, did not rescue 
chromosome alignment in Bub1 RNAi–treated cells (14% of 
Bub1­wt activity) but partially complemented the spindle 
checkpoint response (51–54% of Bub1­wt; Fig. 3, H and I).   
In contrast, cells expressing Bub1–∆conserved motif I did not 
activate the spindle checkpoint (4% of Bub1­wt) but efficiently 
congressed their chromosomes (72% of Bub1­wt; Fig. 3, H and I). 
Additional experiments confirmed the separation of function 
for both types of Bub1 mutants. Bub1–∆kinase domain cells 
treated with Bub1 RNAi failed to align chromosomes on a meta­
phase plate when measured by live cell imaging, whereas ex­
pression of Bub1–∆conserved motif I rescued the timing of 
chromosome alignment in cells treated with Bub1 RNAi (Fig. 4, 
A and B). Conversely, Bub1–∆conserved motif I failed to re­
cruit Mad1, Mad2, and BubR1 to kinetochores in the absence of 
endogenous Bub1, whereas expression of a catalytically inactive 
Bub1 rescued the ability of kinetochores to bind the checkpoint 
proteins (Fig. 4, C–F). We conclude that the kinase activity is 
primarily required for chromosome alignment, whereas the 
conserved domain I is only required for the spindle checkpoint, 
indicating that these two Bub1 functions can be separated.
To obtain a better understanding at the molecular level of 
these two mutants, we tested their ability to rescue the recruit­
ment at kinetochores of three downstream targets of Bub1 that 
are implicated in chromosome congression: CENP­F, Sgo1, and 
MCAK (Johnson et al., 2004; Tang et al., 2004b; Huang et al., 
2007). We detected normal levels of CENP­F and MCAK at   
kinetochores in cells lacking the conserved motif I or cells lacking 
of TUNEL-positive cells after nocodazole and Bub1 RNAi. (H) Mitotic index after 16 h nocodazole treatment normalized to Bub1-wt. (I) Ability to comple-
ment congression errors in cells treated with MG132 normalized to Bub1-wt. Error bars show standard deviation. (J) Immunofluorescence images of 
mitotic cells stained with DAPI (DNA), GFP antisera (green), and CREST sera (red, kinetochores). KD, kinase dead. Insets show a higher magnification 
view of a single kinetochore. Bar, 10 µm.
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Figure 4.  Loss of Bub1 kinase activity, conserved domain I, or kinetochore binding differentially affect chromosome congression and the spindle check-
point. (A) Cumulative frequency plots of chromosome alignment time from live cell videos using nuclear breakdown (NBD) as t = 0. (B) Successive frames 
every 3 min from live cell videos of HeLa Flp-In, Bub1-wt, and Bub1–∆conserved motif I cells transfected with indicated RNAi. (C) Quantification by immuno-
fluorescence of Mad1, Mad2, and BubR1 levels on kinetochores of indicated stable cell lines treated with Bub1 RNAi. Error bars represent standard devia-
tion. (D–F) Immunofluorescence images of the indicated control or Bub1 RNAi–treated prometaphase cell lines stained with Mad1 (D), Mad2 (E), or BubR1 
(F) antisera (green) and CENP-A, or CREST antisera (red, kinetochores). Insets show a higher magnification view of a single kinetochore. Bars,10 µm.849 ANALYZING BUB1 FUNCTION AT THE MOLECULAR LEVEL • Klebig et al.
Figure 5.  Loss of Bub1 kinase activity, conserved domain I, or kinetochore binding differentially affect the recruitment of CENP-F, MCAK, and Sgo1 to kineto-
chores. (A, C, and E) Immunofluorescence images of mitotic control or Bub1 RNAi–treated Bub1 mutant cell lines stained with CENP-F (A), MCAK (C), Sgo1 
(E, green), and CREST antisera (red, kinetochores). Bar, 10 µm. (B, D, and F) Quantification of CENP-F (B), MCAK (D), and Sgo1 (F) levels on kinetochores 
in indicated cell lines relative to Bub1-wt. Insets show a higher magnification view of a single kinetochore. Errors bars represent standard deviation.JCB • VOLUME 185 • NUMBER 5 • 2009   850
Figure 6.  Expression of cancer-related Bub1 mutants differentially affects checkpoint efficiency and chromosome congression. (A) Immunofluorescence 
quantification of total cellular Bub1 mutant levels using Bub1 and GFP antisera. (B) Immunofluorescence quantification of Bub1 mutant levels on kineto-
chores using GFP antisera. (C) Immunofluorescence images of indicated mitotic cells stained with DAPI (DNA), GFP antisera (green), and CREST antisera 
(red, kinetochores). (D) Mitotic index of Bub1 mutant cells treated for 16 h with nocodazole normalized to Bub1-wt. (E) Ability to complement congression 
errors in Bub1 mutant cells treated for 1 h with MG132 normalized to Bub1-wt. (F) Quantification of TUNEL-positive cells after nocodazole and Bub1 
RNAi. (G) Immunofluorescence quantification of Mad1, Mad2, and BubR1 levels on kinetochores in indicated cell lines treated with Bub1 RNAi. Error 
bars represent standard deviation. (H–J) Immunofluorescence images of the indicated control or Bub1 RNAi–treated prometaphase cells stained with 
Mad1 (H), Mad2 (I), or BubR1 (J) antisera (green) and CENP-A or CREST antisera (red, kinetochores). Insets show a higher magnification view of a single 
kinetochore. Bars,10 µm.851 ANALYZING BUB1 FUNCTION AT THE MOLECULAR LEVEL • Klebig et al.
checkpoint, chromosome congression, and the recruitment of all 
tested downstream factors in RPE1 cells in a manner that was 
identical to HeLa cells, indicating that our results were indepen­
dent of the genetic background (Figs. 9, S3, and S4). However, 
we also noted a small number of significant quantitative differ­
ences. First, the functional separation of spindle checkpoint and 
chromosome congression defects was more consistent in RPE1 
than in HeLa cells; Bub1–kinase domain did not rescue chromo­
some congression, but in contrast to HeLa cells, efficiently 
complemented spindle checkpoint activity (Fig. 9, D and E), 
strengthening  our  conclusion  that  Bub1  kinase  activity  only 
plays a minor role in the spindle checkpoint. Bub1–conserved 
domain I still impaired the spindle checkpoint while fully rescu­
ing chromosome alignment, which is in contrast to HeLa cells 
where it led to weak alignment defects (Fig. 9, D and E). Sec­
ond, RPE1 cells expressing two cancer­related Bub1 mutants, 
Y259C and H265N, showed more severe spindle checkpoint de­
fects than the corresponding HeLa cells (Fig. 9, D and E). This 
was particularly true for Bub1­H265N, which fully rescued the 
spindle checkpoint in HeLa cells but only showed a partial com­
plementation in RPE1 cells.
Discussion
We have established an isogenic expression system in HeLa and 
RPE1 cells to investigate the function of Bub1 at the molecular 
level. Even though this system is probably sensitized as a result 
of mild underexpression of exogenous Bub1, it allowed impor­
tant molecular insights into the function of human Bub1. First, 
we conclude that Bub1 can act in a kinetochore­independent 
manner. Second, our results indicate that the spindle checkpoint 
and chromosome alignment functions can be, as in yeast, sepa­
rated in human Bub1; we identify a novel domain within Bub1 
that is specifically required for spindle checkpoint signaling and 
demonstrate that Bub1 kinase activity regulates chromosome 
alignment but does not play a major role in the spindle checkpoint 
(Fig. 10). This separation of function is also reflected at the level 
of downstream effectors: mutants lacking spindle checkpoint 
control cannot load BubR1, Mad2, and to a lesser extent Mad1, 
but recruit Sgo1, whereas mutants defective in chromosome con­
gression fail to recruit Sgo1 but load Mad1, Mad2, and BubR1. 
Finally, analysis of three cancer­related point mutants revealed 
partial defects in Bub1 function, in particular in their ability to 
activate the spindle checkpoint, suggesting that hypomorphic 
Bub1 mutants could contribute to cellular transformation.
Regulation of the spindle checkpoint
Bub1 is required for the loading of the checkpoint proteins Mad1, 
Mad2, and BubR1/Mad3 to kinetochores (Sharp­Baker and Chen, 
2001; Gillett et al., 2004; Johnson et al., 2004; Meraldi et al., 
2004) and has been proposed to regulate the spindle checkpoint 
by phosphorylating the anaphase­promoting complex/cyclosome 
subunit Cdc20 (Tang et al., 2004a; Kang et al., 2008). Our results 
show that lack of catalytic activity either compromises the spin­
dle checkpoint only partially (HeLa cells) or not at all (hTERT­
RPE1 cells). In contrast, we observe a strong correlation between 
the spindle checkpoint response and the ability to recruit BubR1, 
The most interesting mutant was Bub1­Y259C, which did 
not rescue the spindle checkpoint (38% of Bub1­wt), although 
efficiently restoring chromosome congression (86% of Bub1­wt; 
Fig. 6, D and E). Bub1­Y259C cells treated with Bub1 RNAi had 
normal levels of Mad1 but low levels of Mad2 and BubR1 (Fig. 6, 
G–J). Given the usual tight binding of Mad1 to Mad2, we tested 
whether the low levels of Mad2 on kinetochores were caused by 
reduced Mad2 levels or the inability to recruit Mad2 on kineto­
chores by immunoblotting with Mad2 antibodies and found the 
latter to be the case (Fig. S2 C). Thus, we conclude that Bub1­
Y259C fails to rescue the spindle checkpoint as the result of a 
deficient recruitment of Mad2 and BubR1 to kinetochores. Expres­
sion of Bub1­Y259C also rescued the ability of kinetochores to 
bind Sgo1 and CENP­F but not MCAK (Fig. 7). Interestingly, 
Bub1­Y259C was, apart from the null mutants Bub1­Bub3–
binding domain and Bub1­DN, the only Bub1 mutant that did not 
rescue MCAK localization. This suggests that this region of Bub1 
must be critical for MCAK regulation and indicates that Bub1 
does not regulate chromosome alignment through MCAK. Given 
the proximity of the Y259C mutation to the Bub3­binding domain, 
we further tested the ability of Bub1­Y259C and other Bub1 mu­
tants to bind to Bub3 in an in vitro assay. Our analysis revealed that 
all mutants except the ∆Bub3­binding domain and Bub1­DN bind 
to Bub3 even though the binding of Bub1­Y259C was reduced 
compared with Bub1­wt (Fig. S2, D and E). However, this was 
also the case for catalytically inactive Bub1 mutants, which do not 
have strong spindle checkpoint defects and still load MCAK, indi­
cating that the defects observed in cells expressing Bub1­Y259C 
cannot result just from reduced Bub3 binding.
Bub1 mutants in nontransformed  
hTERT-RPE1 cells
To investigate whether Bub1 function depends on its genetic back­
ground, we compared our Bub1 mutant HeLa cell lines with the 
same set of mutants expressed in nontransformed hTERT­RPE1 
(human telomerase­immortalized retinal pigment epithelial) Flp­In 
cells. We generated hTERT­RPE1 cells with a single Flp­In recom­
bination site (Fig. 8 A) in which we stably incorporated Bub1­wt, 
Bub1­KNL1–binding domain, Bub1­Bub3–binding domain, 
Bub1–conserved domain I, Bub1–kinase domain, Bub1­DN, 
Bub1­A130S, Bub1­Y259C, and Bub1­H265N. We first confirmed 
that Bub1 RNAi depleted endogenous Bub1, abolished the spindle 
checkpoint, disrupted chromosome segregation, and impaired the 
recruitment of Mad1, Mad2, BubR1, CENP­F, MCAK, and Sgo1 
to kinetochores in hTERT­RPE1 Flp­In cells (Fig. 8, B–L; Fig. S3; 
and Fig. S4). Stable expression of Bub1­wt­Flag­EGFP suppressed 
apoptosis and completely rescued the spindle checkpoint, chromo­
some congression, and the recruitment of all tested downstream 
kinetochore proteins, indicating that hTERT­RPE1 Flp­In cells are 
suitable for the characterization of Bub1 function in nontrans­
formed cells (Fig. 8, D–L; Fig. S3; and Fig. S4).
In a second step, we verified the expression and localiza­
tion of all tested Bub1 mutants and quantified to which extent 
they rescued apoptosis, spindle checkpoint, chromosome con­
gression, and target protein recruitment (Figs. 9, S3, and S4) 
when compared with HeLa Flp­In cells (Fig. 9, D and E). Quali­
tatively, we found that all the Bub1 mutants regulated the spindle JCB • VOLUME 185 • NUMBER 5 • 2009   852
Figure 7.  Effect of cancer-related Bub1 mutants on the recruitment of CENP-F, Sgo1, and MCAK to kinetochores. (A, C, and E) Immunofluorescence images 
of the indicated control or Bub1 RNAi–treated mitotic cells stained with CENP-F (A), Sgo1 (C), and MCAK (E) antisera (green) and CREST antisera (red, 
kinetochores). Bars, 10 µm. (B, D, and F) Quantification of CENP-F (B), Sgo1 (D), and MCAK (F) levels on kinetochores in the indicated cell lines treated 
with Bub1 RNAi. Insets show a higher magnification view of a single kinetochore. Error bars represent standard deviation.853 ANALYZING BUB1 FUNCTION AT THE MOLECULAR LEVEL • Klebig et al.
Figure 8.  Integration of the FRT site into the genome of hTERT-RPE1 cells does not affect the Bub1 RNAi phenotype, and expression of Bub1-wt-Flag-EGFP   
rescues Bub1 RNAi. (A) FISH analysis of the selected hTERT-RPE1 Flp-In clone with a probe against lacZ. The arrowhead indicates a positive FISH signal. 
Bar, 5 µm. (B) Immunoblot of hTERT-RPE1 Flp-In cell lysates probed with Bub1 and -tubulin antibodies. Black line indicates that intervening lanes have 
been spliced out. (C) Immunofluorescence images of mitotic cells stained with DAPI (DNA), Bub1 (green), and CREST antisera (red, kinetochores).   
Bar, 10 µm. (D) RT-PCR of a region within the 3 UTR of Bub1, the ORF of Bub1, and the housekeeping gene RPS9. (E) Immunoblot of cell lysates of Bub1-wt cells 
treated with RNAi as indicated and probed with Bub1 and -tubulin antibodies. (F) Immunofluorescence images of mitotic cells stained with DAPI (DNA), 
GFP, or Bub1 antisera (green) and CREST antisera (red, kinetochores). Bar, 10 µm. (G) Quantification by immunofluorescence of total Bub1 levels using 
Bub1 antibodies. (H) Quantification of TUNEL-positive cells after nocodazole and Bub1 RNAi. (I) Mitotic index of the indicated cells treated with or without 
nocodazole for 16 h. (J) Quantification by immunofluorescence of Mad1, Mad2, and BubR1 levels on kinetochores. (K) Cumulative plot of percentage of 
metaphase cells with unaligned chromosomes after a 1-h MG132 treatment. (L) Quantification by immunofluorescence of CENPF, Sgo1, and MCAK levels 
on kinetochores. Insets show a higher magnification view of a single kinetochore. Error bars represent standard deviation.JCB • VOLUME 185 • NUMBER 5 • 2009   854
Figure 9.  The hTERT-RPE1 Bub1 mutant cells behave in a manner similar to HeLa cells. (A) Quantification by immunofluorescence of total Bub1 mutant lev-
els using Bub1 and GFP antibodies. (B) Quantification by immunofluorescence of Bub1 mutant levels on kinetochores using GFP antibodies. (C) Quantifica-
tion of TUNEL-positive cells after nocodazole treatment and Bub1 RNAi. (D) Comparison of mitotic index of Bub1 mutant HeLa and hTERT-RPE1 cells treated 
for 16 h with nocodazole normalized to Bub1-wt. (E) Comparison of the ability to complement congression errors in Bub1 mutant HeLa and hTERT-RPE1 cell 
lines treated for 1 h with MG132 normalized to Bub1-wt. (F) Quantification by immunofluorescence of Mad1, Mad2, and BubR1 levels on kinetochores. 
(G) Quantification by immunofluorescence of CENP-F, Sgo1, and MCAK levels on kinetochores. (H) Immunofluorescence images of mitotic cells stained 
with DAPI (DNA), GFP antisera (green), and CREST antisera (red, kinetochores). Insets show a higher magnification view of a single kinetochore. Error 
bars represent standard deviation. Bar, 10 µm.855 ANALYZING BUB1 FUNCTION AT THE MOLECULAR LEVEL • Klebig et al.
rate of chromosome congression defects because cells expressing 
Bub1­KNL1–binding domain have only moderate congression 
defects even though they fail to recruit Sgo1 onto kinetochores. 
Therefore, Sgo1 cannot be the only target of Bub1 that is relevant 
for chromosome congression, and Bub1 must phosphorylate other 
substrates to ensure chromosome alignment in human cells.
Role of Bub1 kinetochore localization
Photoactivation experiments indicate that Bub1 is tightly associ­
ated to unattached kinetochores and has, among the spindle check­
point proteins, the longest residency time at kinetochores (Howell 
et al., 2004; Shah et al., 2004). Moreover, experiments in S. pombe 
show that telomere­tethered Bub1 recruits Mad3 and Bub3 from 
the cytoplasm, leading to the proposal that Bub1 acts as a spindle 
checkpoint scaffold protein at kinetochores (Rischitor et al., 2007). 
Interestingly, loss of kinetochore binding only weakens but does 
not abolish human Bub1 functions. Bub1­∆KNL1–binding do­
main partially rescues the spindle checkpoint, allows the recruit­
ment of Mad1, Mad2, and MCAK, and strongly reduces the rate 
of chromosome congression errors when compared with a full 
Bub1 depletion. We therefore conclude that binding of Bub1 at the 
kinetochore is important but not essential for its checkpoint and 
chromosome congression function. Although Bub1 might act as a 
scaffold for certain proteins such as Mad3/BubR1 or CENP­F, we 
propose that it regulates chromosome segregation primarily through 
mechanisms independent of kinetochore binding.
Interestingly,  our  results  also  suggest  a  kinetochore­ 
independent role for BubR1, which also regulates the spindle 
checkpoint and chromosome alignment (Lampson and Kapoor, 
2005). Indeed, HeLa cells complemented with Bub1–conserved 
domain I do not load BubR1 onto kinetochores yet efficiently align 
their chromosomes on a metaphase plate. Although recent stud­
ies showed that BubR1 can regulate the spindle checkpoint in the 
cytoplasm (Kulukian et al., 2009; Malureanu et al., 2009), our 
data would suggest that it can also control chromosome align­
ment when not bound to kinetochores.
Bub1 cancer-related mutants
The occurrence of Bub1 mutations and differential Bub1 gene and 
protein expression in cancer tissues and cell lines and the occur­
rence of spontaneous cancers in mice expressing low doses of 
Bub1 indicate a possible role of Bub1 in cancer formation (Gemma 
et al., 2000; Shigeishi et al., 2001; Ouyang et al., 2002; Ru et al., 
2002; Shichiri et al., 2002; Hempen et al., 2003; Doak et al., 2004; 
Jeganathan et al., 2007). However, given the multiple roles of Bub1, 
it is unknown which might be the critical function of Bub1 in the 
context of tumorigenesis. Interestingly, all tested Bub1 mutants fail 
Mad2, and to a lesser degree Mad1, to kinetochores. This indi­
cates that BubR1, Mad1, and Mad2 recruitment is the primary 
mechanism by which Bub1 contributes to spindle checkpoint 
signaling and that the kinase activity plays only a minor role in 
checkpoint signaling. Consistent with our findings, we note that 
phospho­specific antibodies that identify putative Bub1 phos­
phorylation sites on Cdc20 fail to detect such a phosphorylation 
event under physiological conditions (Kang et al., 2008). Our 
data also indicate that the binding to Bub3 is essential for Bub1 
function in human cells. This is different for fission yeast Bub1 
because SpBub3 is not essential for the spindle checkpoint 
(Tange and Niwa, 2008).
We further identify a novel conserved 19­aa motif in the 
central part of Bub1, which is required for the loading of BubR1, 
Mad1, and Mad2 to kinetochores but does not control chromo­
some congression. Experiments in yeast reported that the central 
240­aa region, which includes the conserved 19­aa motif, can 
bind Mad1 in cell extracts (Warren et al., 2002). However, when 
we tested for such an interaction in in vitro coimmunoprecipita­
tion experiments, we failed to detect a direct interaction between 
human Mad1 and Bub1 (with or without Bub3; unpublished 
data). Moreover, we find that Mad1 is still recruited when Bub1 
fails to bind to kinetochores. This indicates that Bub1 does not 
act as a Mad1­binding platform on kinetochores but rather that it 
facilitates the recruitment of Mad1/Mad2. Interestingly, we note 
that the conserved motif I contains several invariant serines and 
threonines (Fig. 3 C) and that serine 459 is phosphorylated in the 
presence of unattached kinetochores in Xenopus laevis egg ex­
tracts (Chen, 2004). Thus, it will be important to test in the future 
whether the conserved motif I is also phosphorylated when the 
spindle checkpoint is active and whether this phosphorylation 
contributes to checkpoint signaling in human cells.
Regulation of chromosome alignment
Loss of Bub1 leads to a high number of congression errors in 
human cells (Johnson et al., 2004; Meraldi and Sorger, 2005). 
Catalytically inactive Bub1 mutants do not rescue chromosome 
congression defects in cells depleted of endogenous Bub1. We 
therefore conclude that the enzymatic activity of Bub1 is essen­
tial for the regulation of chromosome alignment. Previous stud­
ies reported that Sgo1 is a key target of Bub1 for chromosome 
congression (Tang et al., 2004b, 2006; Kitajima et al., 2005). 
Consistent with data from X. laevis or S. pombe, we find that 
loss of the kinase domain also impairs loading of Sgo1 onto 
kinetochores (Kitajima et al., 2004; Boyarchuk et al., 2007; Fernius 
and Hardwick, 2007). However, our data also indicate that loss 
of Sgo1 on kinetochores does not strictly correlate with a high 
Figure  10.  Schematic illustration of the im-
portance  of  the  different  Bub1  domains  for 
spindle checkpoint efficiency and chromosome 
congression. Continuous line, high importance; 
dashed line, moderate importance.JCB • VOLUME 185 • NUMBER 5 • 2009   856
lacZ with DIG-dUTP (Roche), and the signal was detected by adding   
CDP-star chemiluminescent substrate (Roche) and exposure to x-ray films.
Immunoblotting and RT-PCR
Whole cell extracts were resolved by SDS-PAGE and transferred to nitro-
cellulose membranes by semidry blotting. Membranes were blocked in block-
ing buffer (5% low-fat dried milk, PBS, and 0.1% Tween 20) and incubated 
with 0.3 µg/ml rabbit anti-Bub1, rabbit anti-Mad2 (1:5,000; Bethyl Labo-
ratories,  Inc.),  or  mouse  anti–-tubulin  (1:10,000;  Sigma-Aldrich)  anti-
bodies  in  blocking  buffer.  Anti–mouse  and  anti–rabbit  HRP-conjugated 
secondary antibodies (Sigma-Aldrich) were applied in blocking buffer and 
developed by enhanced chemiluminescence. For RT-PCR, total RNA was 
isolated as described previously (Chen et al., 2005) and subjected to 
random-primed reverse transcription using SuperScript II Rnase H-Reverse tran-
scription (Invitrogen). PCR reactions were performed with 100 ng template 
DNA. The optimal cycle number was determined as described previously 
(for Bub1 and 3 UTR, 38 cycles; RPS9, 28 cycles; Chen et al., 2003). 
Controls were performed with primers for ribosomal protein S9. PCR prod-
ucts were resolved by electrophoresis, visualized with ethidium bromide, 
and their intensities were measured densitometrically.
In vitro translation and immunoprecipitation
Bub1 mutants and Bub3 were in vitro translated using the TNT T7 Coupled 
Reticulocyte Lysate System (Promega) using 50 µCi [
35S]-methionine (Perkin   
Elmer) for each reaction. Flag-tagged Bub1 mutants were immunoprecipitated 
with anti-Flag M2 affinity gel (Sigma-Aldrich) and equilibrated with TNES 
buffer (50 mM Tris, pH 7.5, 100 mM NaCl, 2 mM EDTA, 1% NP-40, and 
1 mM DTT). After a 2-h incubation at 4°C, the agarose beads were washed 
three times with TNES and loaded onto an SDS-PAGE gel. After exposure to 
x-ray films for autoradiography, the autoradiogram was scanned, and the in-
tensity of the signals was measured using softWoRx (Applied Precision, LLC).
Immunofluorescence microscopy
Cells were fixed, permeabilized, blocked, and imaged as described previ-
ously (McClelland et al., 2007) using a 60× oil NA 1.3 objective on a micro-
scope  (Deltavision  RT;  Applied  Precision,  LLC  )  equipped  with  a  camera 
(CoolSnapHQ; Roper Scientific). The following primary antibodies were used 
for staining: goat anti-Bub1 (1:2,000; this study), human anti-CREST (1:400; 
Antibodies, Inc.), mouse anti–CENP-A (1:1,000; Abcam), mouse anti–-tubulin 
(1:10,000; Sigma-Aldrich), rabbit anti-Sgo1 (1:500; Abcam), rabbit anti–
CENP-F (1:1,000; Abcam), rabbit anti-Mad1 (1:2,000; Meraldi et al., 2004), 
rabbit anti-Mad2 (1:500; Covance), mouse anti-BubR1 (1:1,500; Abcam), 
rabbit anti-MCAK (1:500; Cytoskeleton, Inc.), and rabbit anti-GFP (1:1,000; 
Abcam). The levels of kinetochore-bound protein were quantified as described 
previously (McClelland et al., 2007). For quantification of total Bub1 mutant 
protein expression levels, cells were stained with GFP or Bub1 antibodies, and 
the total signal intensity per cell was measured using a low magnification 20× 
NA 0.45 objective with high optical thickness. We determined the mean inten-
sity and standard deviation of 10 cells for each Bub1 mutant.
Live cell time-lapse imaging and analysis
For live cell imaging, cells were monitored at 37°C in LabTechII (Thermo 
Fisher  Scientific)  chambers  in  Leibovitz’s  L-15  medium  containing  10% 
FCS. Images were acquired every 3 min for 8 h using a 20× NA 0.75 ob-
jective on a microscope (Life; Carl Zeiss, Inc.) equipped with a DAPI-FITC-
Rhod/TR-CY5 (Chroma Technology Corp.) filter set.
Online supplementary material
Fig. S1 shows the TUNEL assay and the immunofluorescence images of 
Mad2, Mad1, and BubR1 in HeLa Flp-In cells after Bub1 RNAi. Fig. S2 
shows  the  quantification  of  Mad2,  Mad1,  BubR1,  MCAK,  Sgo1,  and 
CENP-F levels on kinetochores in Bub1-Bub3–binding domain and Bub1-DN 
cells, the immunoblotting of Mad2 in Bub1-Y259C cells, and the in vitro 
Bub3-binding assay. Figs. S3 and S4 show immunofluorescence images 
of Mad1, Mad2, and BubR1 (Fig. S3) and MCAK, Sgo1, and CENP-F 
(Fig. S4) in hTERT-RPE1 Flp-In cells. Online supplementary material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200902128/DC1.
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to fully rescue Bub1 RNAi. This indicates that Bub1 mutants can 
deregulate chromosome segregation and suggests that cancer for­
mation could be linked to a weakened Bub1 function. A precise 
analysis of the involvement of these Bub1 mutants in tumor forma­
tion should therefore be an important feature in future works. It is 
interesting to note that the tested cancer­related Bub1 mutants lead 
to quantitatively different results in HeLa and hTERT­RPE1 cells, 
suggesting that the regulatory pathways controlling chromosome 
segregation are very similar yet also distinct between transformed 
and untransformed cells.
An important question is whether heterozygous Bub1 muta­
tions are sufficient to disrupt chromosome segregation or whether 
both Bub1 alleles have to be targeted. Although the A130S muta­
tion was present on both alleles, Y259C and H265N were found 
only on one allele, which is accompanied by a wt Bub1 allele 
(Hempen et al., 2003). However, in our expression system, none of 
the Bub1 mutants, including the DN N­terminal Bub1 fragment, 
induced a DN effect on mitotic progression, suggesting that the 
DN effect observed by Taylor and McKeon (1997) requires over­
expression of the mutant protein. Therefore, we speculate that epi­
genetic control mechanisms that down­regulate gene expression 
such as hypermethylation or hypoacetylation of the second allele 
are required to sensitize untransformed cells for Bub1 mutations.
Materials and methods
Antibody production
A GST-tagged Bub1 fragment (aa 336–489) was purified from Escherichia 
coli under native conditions and injected into rabbits (NeoMPS) and goats 
(BioGenes). Rabbit anti-Bub1 antibodies were affinity purified against GST-
tagged Bub1 bound to an AminoLink Plus Immobilization column (Thermo 
Fisher Scientific).
Cell culture, stable cell lines, RNAi, and functional assays
Stable HeLa Flp-In, hTERT-RPE1 Flp-In, and Bub1 mutant cell lines were con-
structed according to the manufacturer’s protocol (Invitrogen). We amplified 
the Bub1 cDNA by PCR and inserted it into the pcDNA5/FRT/V5-His-TOPO 
vector (Invitrogen). Flag-EGFP was subcloned C-terminally of Bub1. The 
mutants were constructed via site-directed mutagenesis. Cells were grown 
at 37°C in 5% CO2 in either Dulbecco’s minimum essential medium + 10% 
FCS (HeLa cells) or 50:50 Ham’s F-12/DME + 10% FCS (hTERT-RPE1 cells). 
HeLa Kyoto H2B-mRED cells (provided by D. Gerlich, ETH Zurich, Zurich, 
Switzerland) were supplemented with 500 µg/ml G418, HeLa Flp-In, and 
hTERT-RPE1 Flp-In cells with 400 µg/ml zeocin, and stable Bub1 mutant 
cells were supplemented with 300 µg/ml hygromycine (HeLa) or 5 µg/ml 
puromycine (RPE1). Cells were transfected as described with 30- (HeLa) or 
40-nM (RPE1) siRNAs (Bub1 siRNA, 5-GAGUGAUCACGAUUUCUAA-3; 
alternative Bub1 siRNA, 5-AAGATGCATTTGAAGCCCAGT-3) and ana-
lyzed 48 h after transfection (Elbashir et al., 2001). Cells were treated for   
1 h with 1 µM MG132 prior to fixation to measure congression efficiency. 
To measure spindle checkpoint activity, cells were treated with 1 nM nocodazole 
for 16 h, and the fraction of rounded-up cells was determined by phase- 
contrast microscopy. To measure apoptosis, cells were incubated with   
1 nM nocodazole for 16 h and fixed with 3.7% formaldehyde in phosphate-
buffered saline, pH 7.4. A TUNEL assay was performed using an in situ cell 
death detection system that contained fluorescein–deoxy UTP (dUTP; Roche).
FISH analysis and Southern blotting
For FISH analysis, chromosome spreads were prepared according to stan-
dard cytogenetic methodology. The sample directed against the LacZ gene 
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